Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20111632 | 0.87 | JAK2 (0.32) | POLBLMNAGAAMEN1KMT2A | |
| SCHEMBL20111636 | 0.79 | MCOLN3 (0.41) | POLBLMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL20111909 | 0.75 | SMYD3 (0.30) | — | |
| SCHEMBL21732885 | 0.75 | CYP2D6 (0.47) | — | |
| SCHEMBL10192196 | 0.74 | POLB (0.41) | POLBLMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL14883722 | 0.74 | LMNA (0.44) | LMNAGAAALDH1A1MAPT | |
| SCHEMBL20111953 | 0.73 | SMYD3 (0.40) | POLBLMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL12026407 | 0.70 | — | — | |
| SCHEMBL13841320 | 0.69 | APOBEC3A (0.46) | POLBLMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL24870380 | 0.69 | EPHX2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128824-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUND | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-04-27 | — | — | US | disclosed |
| WO-2018078360-A1 | MODULATORS OF HEDGEHOG (HH) SIGNALLING PATHWAY | E-THERAPEUTICS PLC (GB) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128824-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUND | KRAS, NRAS, HRAS | POLB 4130/4885LMNA 2194/4885GAA 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.